The protection of an approved medicine against competition from generic medicines that extends beyond the protection conferred by data exclusivity. During this period, applications for generics can be accepted and authorised, but the generic medicines cannot be placed on the market.
More information can be found under 'European Medicines Agency procedural advice for users of the centralised procedure for generic / hybrid applications'.